BIGBEAR
PHARMACEUTICAL
Selinexor has demonstrated significant clinical efficacy in the treatment of relapsed/refractory multiple myeloma and other diseases.
AuthenticGuaranteeFast DeliveryPrivacy Karyopharm Therapeutics, a partner of Antengene, recently announced that the U.S. Food and Drug Administration (FDA) has approved Xpovio (selinexor) f···【More】
Update: 15 Apr,2026Source: BigbearViews: 73
Karyopharm Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) ···【More】
Update: 15 Apr,2026Source: BigbearViews: 76
Karyopharm Therapeutics recently announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has is···【More】
Update: 15 Apr,2026Source: BigbearViews: 73
Karyopharm Therapeutics recently announced that the European Commission (EC) has conditionally approved Nexpovio (selinexor), in combination with dexa···【More】
Update: 15 Apr,2026Source: BigbearViews: 74
The European Commission has granted full marketing authorization to selinexor (Nexpovio) in combination with once-weekly bortezomib (Velcade) and low-···【More】
Update: 15 Apr,2026Source: BigbearViews: 77
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
